Hepatitis C and hepatocellular carcinoma

Hepatitis C Virus - The Stealthy Instigator

• Virus: Enveloped, (+)ssRNA Flavivirus; high genetic variability due to error-prone RNA polymerase.
• Pathogenesis: Chronic inflammation and direct viral protein actions are the key drivers.
  • Inflammation: Persistent immune response → cycles of necrosis & regeneration → fibrosis → cirrhosis.
  • Viral Proteins: Core, NS3, and NS5A interfere with tumor suppressors like p53 and Rb.
• 📌 C for Chronic, Cirrhosis, Carcinoma.

⭐ Unlike Hepatitis B, the HCV genome does not integrate into the host genome; oncogenesis is driven by chronic inflammation and viral protein interference.

Pathogenesis - From Hepatitis to Hepatoma

• Inflammation-Driven Carcinogenesis: Unlike DNA viruses, HCV (an RNA virus) does not integrate into the host genome. The primary driver is chronic inflammation and subsequent hepatocyte turnover.
• Cycle of Damage & Repair: Persistent infection leads to a vicious cycle:
  • Chronic hepatitis → hepatocyte necrosis → compensatory regeneration.
  • This high-turnover state, amidst oxidative stress, fosters mutations.
  • Leads to progressive liver fibrosis and, ultimately, cirrhosis in most cases.
• Key Viral Proteins: HCV Core, NS3, and NS5A proteins interfere with host pathways, inhibiting tumor suppressors like p53 and promoting cell proliferation.

⭐ High-Yield: While cirrhosis is the strongest risk factor, HCV can induce HCC without it. Viral proteins (e.g., NS5A) can directly activate pro-oncogenic pathways like Wnt/β-catenin, promoting carcinogenesis even in a non-cirrhotic liver.

Clinical & Diagnosis - Unmasking the Culprit

• Clinical Course:

  • Acute infection is often asymptomatic; chronic infection is a "silent" disease for decades.
  • Progresses insidiously to fatigue, nausea, and eventually signs of cirrhosis (jaundice, ascites, encephalopathy).

• Diagnostic Workup:

  • Screening: Immunoassay for anti-HCV antibodies. A positive result indicates exposure, not necessarily active infection.
  • Confirmation: HCV RNA testing (PCR) to confirm active viremia.
  • Staging: Liver biopsy or non-invasive elastography to assess fibrosis/cirrhosis.

• HCC Surveillance:

  • For all cirrhotic patients: abdominal ultrasound ± AFP every 6 months.

⭐ Mixed cryoglobulinemia is a classic extrahepatic manifestation, presenting with palpable purpura, weakness, and arthralgias (Meltzer's triad).

Screening & Management - The Vigilant Response

• Universal Screening: All adults aged 18-79 once. Test for anti-HCV antibodies; confirm active infection with HCV RNA PCR.
• HCC Surveillance: For patients with cirrhosis, ultrasound (US) with or without alpha-fetoprotein (AFP) every 6 months.
• Management Goal: Achieve Sustained Virologic Response (SVR) with Direct-Acting Antivirals (DAAs).
  • Regimens like Sofosbuvir/Ledipasvir offer >95% cure rates.
• HCC Treatment: Staged approach.
  • Early: Resection, transplant, local ablation.
  • Advanced: Systemic therapy (e.g., Sorafenib).

⭐ Achieving SVR with DAAs significantly reduces, but does not eliminate, the risk of developing HCC, especially in patients with pre-existing cirrhosis. Surveillance must continue.

High‑Yield Points - ⚡ Biggest Takeaways

• Hepatitis C (HCV) is a major cause of hepatocellular carcinoma (HCC), typically developing over 20-30 years.
• The primary mechanism is chronic inflammation and liver cirrhosis, not direct viral oncogene action.
• Viral proteins like the HCV core protein and NS5A/NS5B disrupt host cell cycle control and apoptosis.
• Unlike HBV, HCV is an RNA virus and does not integrate into the host genome.
• Regular ultrasound screening for HCC is crucial for patients with HCV-induced cirrhosis.